Clinical Trial Update: A Phase II Study of Neoadjuvant FOLFIRINOX [Phase 2]

View source ↗

Summary

Phase II study of neoadjuvant FOLFIRINOX in resectable pancreatic ductal adenocarcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• FOLFIRINOX

Snippet

Sponsor: Indiana University | Conditions: Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-01-31